MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

IQV · NYSE

IQVIA Holdings, Inc.

Health Care · Biotechnology: Commercial Physical & Biological Resarch

Reference price$242.94As of Jul 28, 2026
Market capitalization$40.55B
52-week range$154.50–$247.05
S&P 500 portfolio weight0.06%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$210.00-13.6% vs. reference
Average$241.80-0.5% vs. reference
High$288.00+18.5% vs. reference
11 Buy1 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableJun 2026
Consensus EPS$2.726 estimates
Expected range$2.63–$2.80Low to high EPS
Dec 2026$11.57Street EPS consensus
Dec 2027$12.93Street EPS consensus
Dec 2028$14.57Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+5.9% YoY$16.31B$15.41B
Operating income$2.18B$2.2B
Net income$1.36B$1.37B
Operating cash flow$2.65B$2.72B
Capital expenditures($0.6B)($0.6B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Barchart

Stocks Settle Mostly Higher on Positive Earnings Results

Zacks

IQVIA (IQV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Barchart

Stocks Mixed on Earnings Results and Weakness in Chipmakers

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.